ABC | Volume 113, Nº4, October 2019

Updated Updated Cardiovascular Prevention Guideline of the Brazilian Society Of Cardiology – 2019 Arq Bras Cardiol. 2019; 113(4):787-891 443. WoodwardM, Brindle P, Tunstall-PedoeH; SIGNgroup on risk estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172-6. 444. Tonne C, Schwartz J, MittlemanM, Melly S, SuhH, Goldberg R. Longterm survival after acute myocardial infarction is lower in more deprived neighborhoods. Circulation. 2005;111(23):3063-70. 445. Albert MA, Glynn RJ, Buring J, Ridker PM. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation. 2006;114(24):2619-26. 446. Soares GP, Brum JD, Oliveira GM, Klein CH, Silva NA. Evolução de indicadores socioeconômicos e da mortalidade cardiovascular em três estados do Brasil. Arq Bras Cardiol.2013;100(2):147-56. 447. AlterDA,FranklinB,KoDT,AustinPC,LeeDS,OhPI,etal.Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One. 2013;8(6):e65130. 448. Soares GP, Klein CH, Silva NA, Oliveira GM. Progression of mortality due to diseases of the circulatory systemand human development index in Rio de Janeiro municipalities. Arq Bras Cardiol. 2016;107(4):314-22. 449. Villela PB, Klein CH, Oliveira GM. Evolução da mortalidade por doenças cerebrovasculares e hipertensivas no Brasil entre 1980 e 201Arq Bras Cardiol. 2016;107(1):26-3 450. Lesbaupin I, Mineiro A. O desmonte da nação em dados. Petrópolis: Vozes;2002. 451. Finch CE, Crimmins EM. Inflammatory exposure and historical changes in human life-spans. Science. 2004;305(5691):1736-9. 452. Bloom G. Equity in health in unequal societies: towards health equities during rapid social changes. London: IDS Working Paper; 2000. 453. World Development Report 2000/2001 – Attacking poverty. Oxford: Oxford University Press/World Bank; 2000. 454. Lenfant C. Can we prevent cardiovascular diseases in low- and middle- income countries? Bull World Health Organ. 2001;79(10):980-2. 455. Bhatnagar A. Environmental determinants of cardiovascular disease. Circ Res. 2017;121(2):162-80. 456. Massa KH, Pabayo R, Lebrão ML, Chiavegatto Filho A. Environmental factors and cardiovascular diseases: the association of income inequality and green spaces in elderly residents of São Paulo, Brazil. BMJ Open. 2016;6(9):e011850. 457. Spencer FA, Goldberg RJ, Becker RC, Gore JM. Seasonal distribution of acutemyocardial infarction in the secondNational Registry of Myocardial Infarction. J Am Coll Cardiol. 1998;31(6):1226–33. 458. Argacha J, Bourdrel T, van de Borne P. Ecology of the cardiovascular system: A focus on air-related environmental factors. Trends Cardiovas Med. 2018;28(2):112-126. 459. Rajagopalan S, Al-Kindi S, Brook R. Air pollution and cardiovascular disease. J Am Coll Cardiol. 2018;72(17):2054-70. 460. Brook RD, Franklin B, Cascio W, Hong Y, Howard G, Lipsett M, et al. Air pollution and cardiovascular disease: a statement for healthcare professionals from the Expert Panel on Population and Prevention Science of the AmericanHeart Association. Circulation. 2004;109(21):2655–71. 461. Shanley RP, Hayes RB, Cromar KR, Ito K, Gordon T, Ahn J. Particulate Air Pollution and Clinical Cardiovascular Disease Risk Factors. Epidemiology. 2016;27(2):291-298. 462. Azeka E, JateneMB, Jatene IB, Horowitz ES, Branco KC, Souza Neto JD, et al. Sociedade Brasileira de Cardiologia. I Diretriz brasileira de insuficiência cardíaca e transplante cardíaco, no feto, na criança e em adultos com cardiopatia congênita, da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2014;103(6 Suppl 2):1-126. 463. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza vaccinationandreduction inhospitalizations forcardiacdiseaseandstroke among the elderly. N Engl J Med. 2003;348(14):1322-32. 464. Mangtani P, Cumberland P, Hodgson CR, Roberts JA, Cutts FT, Hall AJ. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdomgeneral practice research database. J Infect Dis. 2004;190(1):1-10. 465. Yap FH, Ho PL, Lam KF, Chan PKS, Cheng YH, Peiris JS. Excess hospital admissions for pneumonia, chronic obstructive pulmonary disease, and heart failure during influenza seasons in Hong Kong. J Med Virol. 2004;73(4):617-23. 466. Seo YB, Choi WS, Baek JH, Lee J, Song JY, Lee JS, et al. Effectiveness of the influenza vaccine at preventing hospitalization due to acute exacerbation of cardiopulmonary disease in Korea from 2011 to 2012. Hum Vacc Immunotherapeutics. 2014;10(2):423-7. 467. Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail. 2014;16(3):264-70. 468. Blaya-Nováková V, Prado-Galbarro FJ, Sarría-Santamera A. Effects of annual influenza vaccination on mortality in patients with heart failure. Eur J Public Health. 2016;26(5)890-2. 469. Fang YA, Chen CI, Liu JC, Sung LC. Influenza vaccination reduces hospitalization for heart failure in elderly patients with chronic kidney disease: a population-based cohort study. Acta Cardiol Sin. 2016;32(3):290-8. 470. Sribhutorn A, Phrommintikul A, Wongcharoen W, Chaikledkaew U, Eakanunkul S, Sukonthasarn A. The modification effect of influenza vaccine on prognostic indicators for cardiovascular events after acute coronary syndrome: observations from an influenza vaccination trial. Cardiol Res Pract. 2016 Mar;2016:4097471. 471. Bhatt AS, DeVore AD, Hernandez AF, Mentz RJ. Can vaccinations improve heart failure outcomes?JACC Heart Fail. 2017;5(3):194-203. 472. Hebert K, Marzouka G, Arcement L, Julian E; Cortazar F, Dias A, et al. Prevalence of vaccination rates in systolic heart failure: a prospective study of 549 patients by age, race, ethnicity, and sex in a heart failure disease management program. Congest Heart Fail. 2010;16(6):278-83. 473. Martins WA, Ribeiro MD, Oliveira LB, Barros LS, Jorge AC, Santos CM, et al. Influenza and pneumococcal vaccination in heart failure: a little applied recommendation. Arq Bras Cardiol. 2011:96(3):240-5. 474. Vardeny O, Claggett B, Udell JA, Packer M, Michael Zile M, Rouleau J, et al. Influenza vaccination in patients with chronic heart failure. The PARADIGM-HF Trial. JACC Heart Fail. 2016;4(2):152-8. 475. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de normas e procedimentos para vacinação. Brasília; 2014. 476. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual dos Centros de Referência para Imunobiológicos Especiais. Brasília;2014. Available from: http://www.saude.pr.gov.br/ arquivos/ File/-01VACINA/ manual_crie_.pdf. Cited 2019 mar 01. 477. Martins WA. Vacinação no cardiopata. In: Rocha RM e Martins WA. Manual de Prevenção Cardiovascular. Rio de Janeiro: SOCERJ, 2017. 478. Nanduri SA, Pilishvili T, Bennett, NM. Pneumococcal vaccines in adults: who, what, when? In: Polland GA. Vaccinations. Philadelphia: Elsevier; 2019. 479. Gualandro DM, Bellei N, Oliveira Jr MT, Montenegro S. Cardiovascular disease and yellow fever. Rev Assoc Med Bra. 2018; 64(1):1-2. 480. Iorio A, BasileoM, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, et al. Influenza vaccination and vitamin k antagonist treatment. A placebo- controlled, randomized, double-blind crossover study. Arch Intern Med. 2010;170(7):609-16. 881